Pesquisar um ensaio clínico
Outras opções de pesquisa
13 Resultado(s)
Ensaio em fase de recrutamento = 
; Ensaio a decorrer = 
; Ensaio concluído = 
; Financiado por um membro do IRDiRC = 
; Membro de uma ERN = 
Ensaio (s) clínico (s) nacional (is)
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A single and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZP-3601, a synthetic parathyroid hormone analog, in healthy subjects and in subjects with hypoparathyroidism - FR
Institution: Information not provided - FR
ALEMANHA
Bayern
WÜRZBURG
BurGER: An Investigator-sponsored Phase 3b Open-label Study of Anti- FGF23 Antibody Burosumab (KRN23) in Adult Patients With X linked Hypophosphatemia (XLH) in GERmany
Lehrstuhl für Orthopädie der Universität Würzburg
Bernhard-Heine-Centrum für Bewegungsforschung
AUSTRIA
OBERÖSTERREICH
LINZ
A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients From Birth to Less Than 1 Year of Age With X-linked Hypophosphatemia (XLH) - AT
Kepler Universitätsklinikum - Med Campus IV.
Universitätsklinik für Kinder- und Jugendheilkunde
ESPANHA
Andalucía
SEVILLA
A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients From Birth to Less Than 1 Year of Age With X-linked Hypophosphatemia (XLH) - ES
Hospital Universitario Virgen del Rocío
Unidad de Nefrología Pediátrica
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Institution: Information not provided - US
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
12-months of Treatment With Burosumab in Children and Adolescents With X-linked Hypophosphatemia: a Prospective Longitudinal Cohort Study
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Fluconazole as a New Therapeutic Tool in Hypercalciuric Patients With Increased 1,25(OH)2D Levels
Institution: Information not provided - FR
FRANCA
ILE-DE-FRANCE
PARIS
ACTICAS : A Randomized Crossover Trial to Compare Recombinant Human rhPTH(1-34) to the Association Alfacalcidol/Hydrochlorothiazide in the Treatment of Severe Primary Hypoparathyroidism (Phase II)
AP-HP. Centre - Université de Paris - HEGP Hôpital Européen Georges Pompidou
Centre d'investigation clinique (CIC1418)
IRLANDA
County Dublin
ADDRESS: NOT PROVIDED - IE
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH)-IE
Institution: Information not provided - IE
ESTADOS UNIDOS
Maryland
BALTIMORE
Study of Growth Hormone Use in Patients With Pseudohypoparathyroidism Type 1a (Subtype of Albright Hereditary Osteodystrophy) (Phase 2/3) - US
Kennedy Krieger Institute
Ensaio (s) clínico (s) multinacional (ais)
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A single and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZP-3601, a synthetic parathyroid hormone analog, in healthy subjects and in subjects with hypoparathyroidism
Institution: Information not provided - FR
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US